SETD2 and breast carcinoma: Several epigenetic regulators, such as LSD1, SETD2, and DNMTs were reported to suppress the expression of type I IFNs and ISGs and therefore tumor immunogenicity, suggesting that this might represent a common mechanism utilized by cancer cells.[48] The dual activities of KDM5C, activating estrogen‐target genes and repressing type I IFNs and ISGs, were confirmed in xenograft mouse models, which might together contribute to its oncogenic nature in ERα‐positive breast cancers.